XML 40 R27.htm IDEA: XBRL DOCUMENT v3.26.1
REVENUE RECOGNITION (Tables)
3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
SCHEDULE OF DISAGGREGATED BY PRODUCT

Revenue disaggregated by product for the three months ended March 31, 2026 and 2025 is as follows:

 

Product  2026   2025 
   Three Months Ended 
   March 31, 
Product  2026   2025 
ARBLI™ (SCN-102, Losartan Potassium Oral Suspension)  $56,325   $- 

Pharmaceutical product resale

   -    10,258 
Total revenues  $56,325   $10,258